Sabin Vaccine Development

Press Release--Candidate for First Human Hookworm Vaccine Enters Phase 1 Clinical Trial in Brazil

Below is the latest Sabin Vaccine Institute press release announcing the start of a Phase 1 clinical trial for the first human hookworm vaccine.

Candidate for First Human Hookworm Vaccine Enters Phase 1 Clinical Trial in Brazil

WASHINGTON, DC-- Jan. 19, 2012--The Sabin Vaccine Institute (Sabin) today announced the start of a Phase 1 clinical trial of its Na-GST-1 antigen, a candidate for the first human hookworm vaccine. The trial is a major milestone for the vaccine product development partnership (PDP) headquartered at Sabin.

• Read more

Tropical medicine research moving forward in Texas

In an op-ed published Friday, Sabin president Peter Hotez, M.D., Ph.D., and his Baylor College of Medicine colleague, William Brinkley, Ph.D., applaud the dramatic gains Texas institutions have made to become leaders among the global scientific community.

• Read more

Advancing Antipoverty Vaccine R&D in Innovative Developing Countries

By Erin Knievel

Financing research and development (R&D) for neglected tropical disease (NTDs) is a big challenge. The problem? Market failure. Although pharmaceutical companies have the knowledge base and resources to create multi-drug therapies or possible vaccine candidates, the cost/reward benefit is not compelling. To help fill this void, governments and organizations are using alternative market mechanisms to spur R&D development.

• Read more